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1. Introduction 
Acute cystitis is defined as a superficial infection of the bladder mucosa. Approximately 
10% of females are diagnosed with cystitis on an annual basis and over 50% of females will 
have at least one episode of cystitis during their lifetime (Foxman 2002, Foxman et al. 2000). 
Typically, uncomplicated cystitis occurs in late adolescence and during the second and 
fourth decades in females with up to 30% of females 20 to 40 years of age having a history of 
cystitis (Hooton et al. 1996). Symptoms such as fever, chills and flank pain are absent as 
acute cystitis is not associated with involvement of the upper urinary tracts. Risk factors for 
acute cystitis include sexual intercourse, the use of spermicides and ascending bowel flora. 
Males with underlying structural and functional deficiencies of the genitourinary tract may 
also develop acute cystitis (Krieger et al. 1993). After the initial infection many patients tend 
to have recurrence with 25% to 50% of patients having another infection within 1 year. 
Recurrent episodes of cystitis are defined as symptomatic infections that follow the clinical 
resolution of a previous episode after treatment and their incidence is 3% to 5%. 
Although the vast majority of patients presenting with cystitis respond promptly to 
appropriate therapy, early identification and treatment of patients with complicated cystitis 
remains a significant clinical challenge to physicians and urologists. Herein, we discuss 
appropriate management strategies for patients presenting with symptoms consistent with 
both uncomplicated and complicated cystitis. We also place particular emphasis on 
appropriate antimicrobial treatment regimens for cystitis and discuss emerging patterns of 
resistance among different uropathogens. 
2. Acute uncomplicated cystitis 
2.1 Clinical presentation 
Typically, cystitis presents with symptoms that include dysuria, frequency, urgency and 
suprapubic pain. Occasionally, foul smelling urine and haematuria may develop (Fig. 1). 
The likelihood of cystitis in female patients presenting with these symptoms ranges from 
50% to 90% (Bent et al. 2002, Wong et al. 1985). The likelihood cystitis is up to 90% in a 
female patient who has had cystitis and presents with symptoms suggestive of recurrence 
(Gupta et al. 2001a, Gupta et al. 2001b).  As cystitis only affects the mucosal layers of the 
bladder fever and rigors do not develop. Differential diagnosis for females presenting with 
these symptoms should include vaginitis, sexually transmitted infections (STIs) and urethral 
pathology. 
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It is important to differentiate cystitis from other conditions where dysuria may also be 
present. Specific features within the history, physical examination and voided urine may 
differentiate between vaginitis, urethral infections caused by STIs and other miscellaneous 
conditions associated with dysuria. Characteristic features of vaginitis include irritative 
voiding with vaginal irritation and an insidious onset. Urinary symptoms such as frequency, 
suprapubic pain and haematuria are usually absent. The patient may also give a history of 
vaginal discharge and multiple sexual partners. Common causes of STIs are herpes simplex 
virus (HSV), gonorrhoea and chlamydia. Urethritis also causes subacute dysuria and is 
associated with a history of urethral discharge and multiple sexual partners. In male 
patients urethral discharge with inflammatory cells or pyuria is characteristic and common 
causes of urethritis in males include gonorrhoea, chlamydia, HSV and trichomoniasis. 
Culture and immunological analysis are indicated for diagnostic purposes 
 
 
Fig. 1. Common presenting symptoms associated with acute cystitis. Typically, patients 
present with dysuria, frequency, urgency and suprapubic pain. 
2.2 Risk factors  
The most important risk factors for acute cystitis in female patients are previous episodes of 
cystitis and frequent or recent sexual activity as celibate females rarely present with cystitis 
(Scholes et al. 2000). The relative odds of acute cystitis during the first 48 hours after sexual 
intercourse are increased by 60 fold and spermicidal agents increase the risk of infection 
from E. coli or S. saprophyticus by 2 – 3 fold (Fihn et al. 1998, Nicolle et al. 1982, Strom et al. 
1987). Females that frequently develop recurrent episodes of cystitis are more likely to have 
a maternal history of the condition and to have developed their first episode at an early age 
(Fihn 2003, Scholes et al. 2000). In healthy postmenopausal females sexual activity is a less 
important predictor of cystitis in comparison to younger females and oestrogen deficiency is 
believed to play a greater role (Boyko et al. 2002). Recurrent cystitis in postmenopausal 
females is more likely in patients with cystoceles, urinary incontinence and a previous 
history of genitourinary surgery (Raz et al. 2000). Female patients with diabetes mellitus are 
twice as likely to develop cystitis compared to non-diabetic females. The risk of acute cystitis 
also increases in elderly females residing in institutionalised settings with the risk of 
infection showing a direct correlation with increasing age and physical disability (Nicolle et 
al. 2005). 
2.3 Laboratory diagnosis  
A laboratory diagnosis of suspected acute cystitis is based on microscopic urinalysis that 
indicates the presence of pyuria, bacteriuria and haematuria. Pyuria on microscopy has a 
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sensitivity of 95% and a specificity of 70% (Fihn 2003). The presence of bacteriuria has a 
sensitivity of 40% to 70% and a specificity of 85% to 90% depending on the number of 
bacteria identified (Hurlbut and Littenberg 1991). Dipstick analysis for bacteria (nitrite) or 
pyuria (leukocyte esterase) are convenient but remain less sensitive than microscopic 
assessment of the urine. The accuracy of the findings on a culture of midstream urine (MSU) 
depends on how a positive urine culture is defined. Traditionally, 105 cfu/ml is applied to a 
voided urine sample. Although the specificity is high it is important to note that the 
sensitivity is only in the region of 50%. Lowering the threshold to 102 cfu/mL in cases of 
young females with suspected cystitis raises the sensitivity without affecting the specificity 
(Nicolle et al. 2005, Stamm 1982).  Therefore, urine culture remains the definitive diagnostic 
investigation for acute cystitis and the presence of 102 cfu/mL or more of urine indicates 
active infection.  
Admittedly, routine urine culture is not always necessary for diagnostic purposes (McIsaac 
et al. 2002). It is considered more cost-effective to manage and treat patients symptomatic of 
uncomplicated cystitis without an initial urine culture because antimicrobial therapy is often 
completed before culture results are made available. This theory was validated in one study 
that demonstrated pre-therapeutic urine cultures for UTIs increases cost by up to 40% but 
only decreases the duration of symptoms by 10%(Carlson and Mulley 1985). Therefore, in 
females with recent onset of symptoms suggestive of cystitis, without the features of a 
complicated UTI, a urinalysis that is positive for bacteriuria, pyuria, haematuria or a 
combination should provide sufficient evidence of a UTI and a urine culture may be 
omitted. Importantly, a urine culture should be obtained when symptoms and urine 
examination findings leave a diagnosis of cystitis in doubt. In addition, pretherapeutic urine 
cultures are also necessary for managing patients with a recent history of antimicrobial 
therapy. It has also been demonstrated that treating acute uncomplicated cystitis by 
telephone consultation is safe and effective in primary care settings (Barry et al. 2001, 
Fenwick et al. 2000, Saint et al. 1999). Importantly, inclusion criteria for these studies are 
females at low risk (i.e. without a prior history of UTI, without symptoms suggestive of 
vaginitis or cervicitis and less than 55 years of age). Females that do not meet these criteria 
should be seen in person and examined (Fenwick et al. 2000). 
2.4 Causative microorganisms  
E. coli is the responsible uropathogen in 75% to 90% of female patients diagnosed with acute 
cystitis and Staphylococcus saprophiticus acoounts for 10% to 20% of cases (Jordan et al. 
1980, Latham et al. 1983, Ronald 2002). Less common organisms include Klebsiella, Proteus 
and Enterococci. E. coli and other Enterobacteriaceae are the most commonly diagnosed 
organisms in male patients. 
2.5 Management  
A 3 day course of oral trimethoprim- sulfamethoxazole (TMP-SMX) results in eradication of 
pathogens within 7 days after commencing treatment in approximately 94% of females 
(Warren et al. 1999). Single-dose treatment is less efficacious than the 3 day course with 
eradication rates approaching 87%; however single-dose treatment is associated with fewer 
side-effects (11% versus 18%) (Warren et al. 1999). TMP-SMX is effective and inexpensive for 
empirical therapy. Therefore, TMP-SMX is recommended in areas where the prevalence of 
resistance to these drugs among E. coli strains causing cystitis is less than 20%(Warren et al. 
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1999). When used alone, TMP is as efficacious as TMP-SMX and is associated with fewer 
side effects, probably because of the absence of the sulfa component. It can be prescribed to 
patients who are allergic to sulfa.  
Interestingly, a number of more recent studies have demonstrated that resistance to TMP-
SMX is increasing in many different countries (Bean et al. 2008, Daza et al. 2001, De 
Francesco et al. 2007, Ling et al. 2006, Sader et al. 2005) (Fig. 2). One study from Israel 
demonstrated that 29% of cultures grew TMP-SMX resistant organisms in patients with 
uncomplicated cystitis. In this study microbiological cure was achieved in 86% of patients 
with TMP-SMX susceptible microorganisms but in only 42% of those with TMP-SMX 
resistant organisms (Raz et al. 2002). Another prospective study from the United Kingdom 
(UK) demonstrated resistance to TMP in 13.9% of isolates and patients with resistant isolates 
had a longer median time to symptom resolution (7 versus 4 days; p=0.0002), more frequent 
revisits to their attending physician (39% versus 6% in the first week, p<0.0001), more 
subsequent antibiotics (36% versus 4% in the first week, p<0.0001) and higher rates of 
subsequent bacteria at 1 month (42% versus 20% with susceptible isolates) (McNulty et al. 
2006). Recent studies from the United States have demonstrated TMP-SMX resistance rates 
of 15% to 23% in isolates from patients with acute uncomplicated cystitis (Colgan et al. 2008, 
Hames and Rice 2007). In a study from Japan 17% of isolates from patients with cystitis 
showed resistance to TMP-SMX and abandonment of TMP-SMX as first line therapy for 
acute uncomplicated cystitis is currently under consideration in this region (Yamamoto et al. 
2009). 
 
 
Fig. 2. Increasing rates of resistance for TMP-SMX treatment regimen for acute 
uncomplicated cystitis. 
Resistant strains can be partially predicted from a history of recent antimicrobial usage. It 
has also been demonstrated that females who have been treated with TMP-SMX are 16 times 
less likely to be re-infected with an isolate resistant to this agent compared with females 
who have not take recent antimicrobial therapy (Brown et al. 2002).  Furthermore, females 
that have taken other antimicrobial agents are two-fold more likely to be infected with a 
resistant isolate. Although the resistance rate to TMP-SMX is as high as 20% in some regions 
the bacteriologic eradication rate is approximately 80% and the clinical cure rate is 
approximately 85% (Manges et al. 2001, Wright et al. 1999). On account of these increasing 
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resistance rates some authorities advocate the following criteria for prescribing TMP-SMX 
(Gupta et al. 2001b, Steinke et al. 1999): 
 No known drug allergy 
 No recent history of antibiotic usage 
 Local prevalence to resistance is less than 15 – 20% 
Although less than 5% of urine isolates are resistant to nitrofurantoin, it is considerably less 
active than TMP-SMX against aerobic Gram-negative rods other than E. coli. Furthermore, 
nitrofurantoin is more expensive than TMP-SMX. It is usually well tolerated, however it is 
frequently prescribed for 7 days and this may cause significant gastrointestinal upset. The 
macrocrystalline formulation is taken every 6 hours and the monohydrate macrocrystal is 
taken twice daily. The monohydrate formulation is associated with fewer side-effects. 
Nitrofurantoin is not associated with plasmid-mediated resistance and is a suitable choice 
for patients with recent exposure to other antimicrobial agents (Fihn 2003). 
Fluoroquinolones offer excellent activity and are usually well tolerated (Henry et al. 2002). 
Their resistance is less than 5% in most regions (Hooton et al. 2004, Warren et al. 1999); 
however resistance rates are beginning to increase worldwide (although not as high as that 
of TMP-SMX) (Yamamoto et al. 2010) (Muratani and Matsumoto 2006). In the Mediterranean 
region up to one-third of strains that demonstrate reduced susceptibility to flouroquinolones 
and cause uncomplicated cystitis belong to two clonal groups: O15:H1 and O25:H4 
(Cagnacci et al. 2008). This implies that strains belonging to these two clonal groups play a 
major role in determining the increasing rate of flouroquinolone resistant E. coli strains in 
the community. One study from Japan reported fluoroquinolone resistance in 8% of isolates 
from patients with acute uncomplicated cystitis (Yamamoto et al. 2009). Worryingly, 
resistance rates for E. coli isolated from acute uncomplicated cystitis to ciprofloxacin 
increased from 15.2% in 2002 to 23.4% in 2006 in South Korea (Yamamoto et al. 2010) (Fig. 3). 
 
 
Fig. 3. Increasing rates of resistance for E. coli against ciprofloxacin in South Korea from 
2002 to 2006.  
The efficacy of ofloxacin is greater than TMP-SMX with recurrence rates of 8% to 9% 6 
weeks after therapy has been completed (Hooton et al. 1991). Other fluoroqinolones have 
similar efficacy however they should be regarded as a second line treatment option due to 
their high cost and to preserve their sensitivity against uropathogens. Their use for 
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uncomplicated cystitis should be limited to patients that are allergic to less expensive drugs, 
to patients with previous exposure to antimicrobial agents causing bacterial resistance and 
to regions where resistance to TMP-SMX is greater than 20%. When TMP-SMX is 
contraindicated a 3 day course of ciprofloxacin, levofloxacin, norfloxacin, lomefloxacin or 
gatifloxacin is an appropriate alternative. Importantly, fluoroquinolones are less active 
against S. saprophyticus and many Gram-negative uropathogens (Fihn 2003).  
Fosfomycin tromethamine is taken as a single dose of powder from a sachet and is another 
option for treating uncomplicated cystitis. It is less effective than TMP-SMX and 
fluoroquinolones and should only be considered when more effective agents cannot be 
prescribed (Warren et al. 1999). Further limitations of fosfomycin tromethamine are its poor 
efficacy against S. saprophyticus and its expensive nature. The high in vitro resistance to 
ampicillin and sulfonamide and the high cost of amoxicillin/clavulanate and the 
cephalocrystalline sporins limit their usefulness in the setting of acute uncomplicated 
cystitis. More than 90% of females report the absence of acute urinary symptoms within 72 
hours after commencement of antimicrobial therapy (Fihn et al. 1988). Phenazopyridine or 
Uristat can be prescribed in females with severe persistent dysuria. Although this 
compound is available over the counter there is concern that females with severe dysuria are 
not seeking medical care and are also at risk of side effects such as headache, 
gastrointestinal upset, rash and nephrotoxicity (Fihn 2003). Resistance rates of E. coli to 
antibiotic regimes are illustrated in Table 1.  
 
Antimicrobial Agent Italy Spain USA UK China Japan 
Ampicillin 49 65 - 54 - - 
Amoxicillin/clavulanate 8 37 12 12 29 2 
Piperacillin 30 - - - - - 
Piperacillin/ tazobactam 1 68 - - 7 - 
Nitrofurantoin 9 7 3 5 - 1 
TMP - - - 39 - - 
TMP-SMX 27 37 20 - - 10 
Ciprofloxacin 19 22 5 9 51 8 
Gentamicin 6 10 - 5 39 2 
Cefalexin - - - 8 - - 
Cephazolin 7 - - - - - 
Cefpodoxime - - 2 6 - 5 
Cefuroxime - 13 24 - - - 
Cefprozil - - 3 - - - 
Cefotaxime - 4 - - 14 - 
Ceftazidime - - - - 3 - 
Ceftriaxone 2 - - - - - 
Cefdinir - - 2 - - 5 
Cefoperazone - - - - 17 - 
Cefperazone/sulbactam - - - - 5 - 
Cefipime - 3 - - 8 - 
Table 1. Resistance rate of E. coli isolated from patients with community acquired infections 
(depicted as percentage) (Bean et al. 2008, Daza et al. 2001, De Francesco et al. 2007, Ling et 
al. 2006, Sader et al. 2005, Yamamoto et al.). 
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2.5.1 Cranberry juice  
Proanthocyanidins found in cranberry juice have been long advocated to play a preventative 
role against cystitis. It appears that proanthocyanidins inhibit the attachment of 
uropathogens to the surface of the uroepithlium. Randomised trials suggest that 200-750 ml 
of cranberry juice or cranberry-concentrate tablets reduce the risk of symptomatic recurrent 
infection by 12-20%(Avorn et al. 1994, Kontiokari et al. 2001, Stothers 2002). Interestingly, 
the amount of cranberry juice found within products marketed as cranberry juice is highly 
variable and ranges from 5-100%. 
2.6 Duration of therapy  
In female patients with uncomplicated cystitis 3 days of therapy is the preferred treatment 
regimen. One study that reviewed over 300 clinical trials of single-dose, 3-day or 7-day 
treatment with TMP-SMX, fluroquinolones and β-lactam antimicrobial agents found that 3-
day therapy is more effective than single-dose therapy (Table 2). In addition, 3-day therapy 
with TMP-SMX, amoxicillin or cloxacillin is associated with cure rates that are comparable 
with longer courses of therapy and an incidence of adverse effects that are as low as single-
dose therapy (Warren et al. 1999). Seven-day therapy is associated with a higher incidence of 
adverse effects and is only recommended in females with symptoms longer than 1 week, in 
male patients and in individual patients that have complicating risk factors 
 
Circumstance Drug Dosage Frequency Duration 
(Days) 
Female 
Healthy Ciprofloxacin 500mg BD 3 
Levofloxacin 500mg QDS 3 
TMP-SMX 1 double 
strength 
tablet (160 – 
800mg) 
BD 3 
Trimethoprim 100mg BD 3 
Nitrofurantoin 100mg BD 3 
Norfloxacin 400mg BD 3 
Symptoms >7 
days, recent UTI, 
Age >65 years, 
Diabetes, 
Diaphragm use  
TMP-SMX As Above As Above 7 
Fluoroquinolone   7 
Pregnancy Amoxicillin 250mg TDS 7 
Cephalexin 500mg QDS 7 
Nitrofurantoin As Above As Above 7 
Males 
 Fluoroquinolone As Above As Above 7 
TMP-SMX As Above As Above 7 
Table 2. Current treatment regimens for acute uncomplicated cystitis.  
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2.7 Cost of therapy  
The cost of treating acute uncomplicated cystitis involves the initial evaluation, the cost of 
the drug administered and the subsequent follow-up (Table 3). Good cost effectiveness is 
achieved with adequate efficacy against the most common uropathogen, E. coli. Intuitively, 
the lower the effectiveness against E. coli, the greater number of revisits, cases of 
progression to pyelonephritis and the higher the follow-up cost. Notably, antimicrobial cost 
is a poor predictor of cost-effectiveness as demonstrated in one study that compared the 
most expensive and least expensive drugs (fluroquinolones and TMP-SMX respectively). 
Results showed that both regimens are equally cost effective and that both of these drugs 
are also more cost effective against nitrofurantoin (Rosenberg 1999). 
 
Antimicrobial Agent 
Approximate 
Retail Cost ($) 
Side effects 
Trimethoprim-
sulfamethoxazole (TMP-
SMX) 
1.83 
Anorexia. Nausea, vomiting, rash, 
urticaria, blood dyscrasias, 
hypersensitivity, hepatic necrosis 
Trimethoprim 4.33 
Diarrhoea, rash, glossitis, taste changes, 
blood dyscrasias, hypersensitivity 
Norfloxacin 25.21 
Dizziness, restlessness, headache, 
diarrhoea, nausea, rash, vaginitis, 
convulsions, psychosis, hypersensitivity, 
tendon rupture 
Ciprofloxacin 53.56 Similar to norfloxacin 
Levofloxacin 43.92 Similar to norfloxacin 
Gatifloxicin 21.61 Similar to norfloxacin 
Lomefloxacin 35.96 Similar to norfloxacin 
Nitrofurantoin 
macrocrystals 
35.29 
Anorexia, nausea, vomiting, headache, 
pulmonary hypersensitivity, 
hepatotoxicity, haemolytic anaemia, 
peripheral neuropathy 
Nitrofurantoin 
monohydrate macrocrystals 
29.96 
Similar to nitrofurantoin macrocrystals 
(gastrointestinal effects less common) 
Fosfomycin tromethamine 33.97 
Nausea, vomiting, vaginitis, rash, 
hypersensitivity 
Table 3. Cost of treatment regimens for acute uncomplicated cystitis (Rosenberg 1999). 
2.8 Follow-up  
In general, young female patients that are asymptomatic after antimicrobial therapies do not 
require a follow-up visit or repeat MSU. A follow up visit is recommended with MSU in 
older females and in all male patients with cystitis. Urological evaluation with ultrasound, 
computed tomography (CT) or cystoscopy is unnecessary in females and is also usually 
unnecessary in male patients that respond appropriately to antimicrobial therapy 
(Abarbanel et al. 2003, Lipsky 1989). However, one study demonstrated that up to 50% of 
males with UTIs have a significant urological abnormality. Finally, patients that do not 
respond to antimicrobial therapy should undergo appropriate microbiological evaluations 
(Andrews et al. 2002). 
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3. Asymptomatic bacteriuria  
Asymptomatic bacteriuria can be defined as a microbiological diagnosis based on the 
isolation of a specified quantitative count of bacteria in a properly collected specimen of 
urine from a patient who is without symptoms or signs consistent with cystitis. Absence of 
symptoms is usually obvious in healthy patients, however an asymptomatic UTIs may be 
more difficult to diagnose in catheterised or neurologically compromised patients. A single 
catheterised urine specimen with a solitary isolate of 102 cfu/mL is diagnostic of bacteriuria 
in catheterised male and female patients (Nicolle et al. 2005). Concomitant pyuria ranges 
from 30% in young females to 100% in catheterised patients (Hooton et al. 2000). 
Importantly, other co-factors like bladder calculi can induce mucosal inflammation in this 
patient cohort. Therefore, the presence of pyuria alone is insufficient for a diagnosis of 
bacteriuria. 
The prevalence of asymptomatic bacteriuria among the general population varies with age, 
gender and the presence of abnormalities in the genitourinary tract (Nicolle et al. 2005) 
(Table 4). E. coli is the most common uropathogen isolated in patients with asymptomatic 
bacteriuria and it is usually a less virulent strain than in isolates from symptomatic patients 
(Svanborg and Godaly 1997). Enterobactericeae and Gram-positive uropathogens are more 
commonly isolated in patients with abnormalities of the genitourinary tract. Pseudomonas 
aeruginosa and Proteus are more prevalent among patients living in residential care. 
 
Patient Population Prevalence (%)
Premenopausal females 1.0 – 5.0 
Pregnant females 1.9 – 9.5 
Postmenopausal females (age: 50-70) 2.8 – 8.6 
Diabetic patients 
Males 0.7 - 11 
Females 9.0 - 27 
Elderly patients in the community 
Males  3.6 - 19 
Females 10.8 - 16 
Elderly patients in nursing homes 
Males 14 -50 
Females 25 – 50 
Patients with spinal cord injuries 
Self-intermittent catheterisation (SIC) 23 – 89 
Sphincterotomy and condom catheter in situ 57 
Patients undergoing haemodialysis 28 
Indwelling catheter 
Short-term 9 – 23 
Long-term 100 
Table 4. Prevalence of asymptomatic bacteria among different patient populations (Nicolle 
et al. 2005). 
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3.1 Management of asymptomatic bacteriura  
In general, management of asymptomatic bacteriuria is governed by the patient cohort and 
their risk factors for adverse outcomes that may be prevented with appropriate 
antimicrobial treatment. In adult populations it has been shown that asymptomatic 
bacteriuria is not harmful and treatment of asymptomatic bacteriuria does not decrease the 
frequency of symptomatic UTIs or improve patient outcomes. Therefore, screening and 
treating asymptomatic bacteriuria is discouraged in populations other than in pregnant 
females and in patients undergoing urological procedures (Nicolle et al. 2005) (Table 5). 
 
Patient Cohort Recommended Not recommended 
Premenopausal non pregnant females  X 
Pregnant females X  
Diabetic females  X 
Elderly patients residing in the community  X 
Elderly patients residing in nursing homes  X 
Patients with spinal cord injuries  X 
Patient with indwelling catheters*  X 
Urological inteventions X  
Immunocompromised patients  X 
*Antimicrobial treatment of asymptomatic female patients with catheter-associated bacteriuira 
persisting >48 hours should be considered. 
Table 5. Algorithm for screening and treating asymptomatic bacteriuria (Nicolle et al. 2005). 
4. Complicated cystitis  
Complicated cystitis may occur in patients with a compromised urinary tract or by a very 
resistant uropathogen. The clinical spectrum of complicated cystitis can range from mild 
cystitis to life-threatening infections of the kidney and urospesis (Table 6). Urine cultures are 
mandatory to identify the invading uropathogen and its antimicrobial susceptibility in this 
group of patients. The following are common host-factors that predispose to complicated 
cystitis: 
 Functional and/or structural abnormalities of the urinary tract 
 Recent instrumentation of the urinary tract 
 Recent usage of antimicrobial therapy 
 Diabetes mellitus 
 Immunosuppression 
 Pregnancy 
 Hospital-acquired infections 
Due to the wide range of host conditions and uropthogens that are associated with 
complicated cystitis appropriate guidelines for empirical therapy remain limited. Patients 
with mild to moderate illness can be treated on an outpatient basis with oral 
fluroquinolones. If the susceptibility pattern of the pathogen is known TMP-SMX may also 
be effective (Stamm and Hooton 1993). 
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Pathogens 
Mitigating 
Circumstances 
Recommended Empirical Treatment 
E. coli, Proteus 
species, Klebsiella 
species, 
Pseudomonas 
species 
Mild-to-moderate 
illness, no nausea or 
vomiting-outpatient 
therapy 
Oral* norfloxacin, ciprofloxacin or 
ofloxacin for 10-14 days 
Serratia species, 
enterococci, 
staphylococci 
Severe illness or 
urospesis- 
hospitalisation 
required 
Parenteral** ampicillin and gentamicin, 
ciprofloxacin, levofloxacin, ceftriaxone, 
aztreonam, ticarcillin- clavulanate or 
imipenem-cilastin until fever has 
subsided; then oral trimethoprim-
sulfamethoxazole, norfloxacin, 
ciprofloxacin or levofloxacin for 14-21 
days 
* Oral regimens for pyelonephritis and complicated UTI are as follows: trimethoprim-sulfamethoxazole, 
160 to 800 mg, BD; norfloxacin, 400mg, BD; ciprofloxacin, 500 mg, BD; levofloxacin, 500 mg, 500 
mg/day. 
** Parenteral regimens are as follows: ciprofloxacin, 400mg, BD; levofloxacin, 500mg/ day; gentamicin 
1mg/kg TDS; ceftriaxone, 1-2 g/ day; ampicillin, 1 g QDS; imipenem-cilastin, 250-500 mg QDS; 
ticarcillin-clavulanate, 3.1 g QDS; and aztreonam 1 g TDS. 
Table 6. Treatment strategies for complicated cystitis (Stamm and Hooton 1993). 
For hospitalised patients intravenous ampicillin and gentamicin provides adequate 
coverage against most pathogens. Antimicrobial therapy can also be modified when 
sensitivity data are available. Therapy is usually continued for 10 to 14 days and switched 
from parenteral to oral whenever possible. Repeat urine culture should be performed 7 and 
14 days after therapy to ensure adequate efficacy has been achieved (Fihn 2003).  
4.1 Unresolving cystitis  
Persistent infection suggests that initial antimicrobial therapy has been inadequate at 
eliminating bacterial growth and concomitant symptoms from the genitourinary tact. Repeat 
urinalysis and MSU are indicated if the symptoms of UTI do not resolve by the end of 
treatment or if symptoms begin to recur shortly after therapy. If the patient’s symptoms are 
severe it is prudent to commence empirical therapy with a fluoroquinolone until the MSU 
results have been obtained. 
Resistance to the antimicrobial agent selected to treat the infection is the most common 
cause for patients with persistent unresolving UTIs. The patient may have a recent history of 
antimicrobial therapy and colonisation of the bowel with resistant bacteria has subsequently 
developed. In addition, tetracycline, sulfonamides and β-lactams cause plasmid-mediated R 
factors that simultaneously carry resistance to multiple antimicrobial agents. The 
development of resistance in a previously susceptible population of bacteria is the second 
most common cause of resistant UTIs and this issue may arise in up to 5% of patients that 
are receiving antimicrobial therapy. Resistance to antimicrobial therapy is easily diagnosed 
as the culture taken on therapy shows that the previously susceptible population has been 
replaced by resistant bacteria of the same species. More resistant strains of bacteria usually 
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emerge when the concentration of antimicrobial therapy in the urine is insufficient to 
eradicate all bacteria present. This phenomenon usually occurs in patients who are 
underdosed and in patients who are poorly compliant with their prescribed regimen. Rapid 
reintroduction of a new resistant species while the patient is undergoing antimicrobial 
therapy may also cause resistant UTI. Reinfection mimicking unresolved bacteriuria should 
increase the index of suspicion for an enterovesical fistula. The following list represents the 
more common causes of persistent unresolving cystitis 
 Bacterial resistance to the antimicrobial agent selected for treatment. 
 Development of resistance from previously susceptible bacteria 
 Bacteriuira resulting from 2 different bacterial species with different susceptibilities 
 Reinfection with a new, resistant species during initial therapy for the original 
susceptible organism 
 Azotemia 
 Analgesia abuse leading to papillary necrosis 
 Staghorn calculi providing a nidus for resistant bacteria to attach 
If the repeat urine culture (obtained from when the patient was on therapy) demonstrates 
that the initial bacterial species is still present and susceptible to the antimicrobial agent 
selected to treat the infection, it is likely that the unresolved infection is caused by an 
inability to deliver sufficient concentrations of antimicrobial agents into the urinary tracts 
or an excessive number of bacteria may be over-riding the activity of the antimicrobial 
agent.  
In addition, antimicrobial levels are usually lower than the minimal inhibitory concentration 
required for eradicating the infecting organism in patients with uraemia. Severe defects in 
the medullary collecting system impair the kidney’s concentrating ability and can dilute the 
antimicrobial agent, particularly in patients with papillary necrosis. Large masses of bacteria 
within the genitourinary tract are frequently seen with a large staghorn calculus. In this 
situation the urinary concentration of antimicrobial agent may be large, however it may be 
inadequate to sterilise the large volume of infected urine. This phenomenon may occur 
because susceptible bacteria cannot be inhibited once a specific critical density is reached. 
Rarely, patients with a variant of Munchausen’s syndrome may present with unresolving 
cystitis. These patients tend to inoculate their bladders with uropathogens or wilfully avoid 
antimicrobial agents. Careful bacteriologic observations usually indicate the implausibility 
of the clinical picture. 
4.2 Laboratory diagnosis  
In cases of unresolving cystitis urinalysis and urine culture are required to investigate the 
uropathogen responsible for the persistent infective process. Renal function and imaging of 
the genitourinary tract should be performed if repeat culture demonstrates sensitivity of the 
uropathogen to the antimicrobial agent presecribed. This investigative regimen is employed 
to identify any abnormalities within the urinary tract. Empirical treatment of unresolving 
cystitis is based on the assumption that the infecting uropathogen is resistant. 
Fluoroquinolones provide sufficient antimicrobial coverage in most situations and should be 
prescribed for 7 days. Adjustments to this regime can be performed when bacterial 
susceptibilities have been made available. Finally, urine cultures should be repeated during 
and 7 days after therapy to ensure adequate eradication has been achieved. 
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4.3 Recurrent cystitis  
Recurrent episodes are caused by re-emergence of bacteria from a site within the urinary 
tract (persistence) or from new infective uropathogens outside the urinary tract (reinfection) 
(Fig. 4). Bacterial persistence must be caused by the same uropathogen on each occasion and 
reinfections typically occur at varying intervals and are usually cause by different species of 
bacteria. It is important to differentiate between persistence and reinfections as management 
protocols differ. Patients with bacterial persistence can be cured of recurrent cystitis by 
indentifying and surgically removing/ correcting the focus of infection. Patients 
complaining of recurrent reinfection usually require long-term medical management as a 
structural defect is not usually present. Reinfections in males occasionally occur and are 
usually as a result of an underlying abnormality such as urethral stricture. In these 
situations surgical evaluation is warranted. 
 
 
Fig. 4. Re-emergence of bacteria from within the urinary tract (persistence) or invasion of 
new bacteria (reinfection) is the most common causes of recurrent cystitis. 
4.3.1 Bacterial persistence  
After the initial episode has resolved recurrence with the same organism arises from a site 
within the genitourinary tract. The site of bacterial persistence is usually excluded from high 
concentrations of the antimicrobial agent. It is generally accepted that there are 12 
correctable urological abnormalities that may cause bacteria to persist within the 
genitourinary tract. These abnormalities are illustrated in Table 7 and may be difficult to 
diagnose. Some causes may require cystoscopic localisation of the infection (with ureteral 
catheters) to accurately define the focus of bacterial persistence.   
 Infected stones 
 Chronic bacterial prostatitis 
 Unilateral infected atrophic kidneys 
 Ectopic ureters and ureteral duplication 
 Foreign bodies 
 Urethral diverticula and infected periurethral glands 
 Unilateral medullary sponge kidneys 
 Non-refluxing, normal appearing, infected ureteral stumps after nephrectomy 
 Infected urachal cyst 
 Infected communicating cysts of the renal calyces 
 Papillary necrosis 
 Perivesical abscess with fistula to bladder 
Table 7. Urological abnormalities causing bacterial persistence that may be amenable to 
surgical correction.  
It is important to identify patients with bacterial persistence as they represent the only 
patient cohort with a surgically curable cause of recurrent UTIs. Radiological and 
endoscopic evaluation of the urinary tract is necessary with excreting urography/ CT and 
cystoscopic assessment providing the initial screening investigations. Diverticulum and 
nonrefluxing ureteral stumps can be diagnosed with retrograde urography. In patients in 
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whom the focus of infection cannot be eradicated, long-term, low-dose antimicrobial 
suppression is necessary to prevent symptoms of infection. The antimicrobial drugs used for 
low-dose prophylaxis will also be effective for bacterial suppression if the persistent strain is 
susceptible. These include nitrofurantoin, TMP-SMX, cephalexin, and the fluoroquinolones 
4.3.2 Recurrent infections  
Females with recurrent infections and who are exposed to vaginal spermicides from either 
condoms or diaphragms should consider alternative methods of contraception or protection 
from sexually transmitted infections (STIs). Continuous and postcoital prophylaxis with 
low-dose antimicrobial agents is effective in treating recurrent cystitis and prophylactic 
treatment should not be commenced until active infection has been eradicated (Hooton 
2001). Absence of infection can be confirmed by a negative urine culture 1-2 weeks after 
treatment has been discontinued.  
Continuous prophylaxis is a potential option for females who have had 2 or more 
symptomatic infections over a 6 month period. Randomised, placebo-controlled trials have 
demonstrated that continuous prophylaxis with nitrofurantoin, trimethoprim (± 
sulfamethoxazole), ciprofloxacin or norfloxacin decreases recurrent episodes by 95% (i.e. 
from 2 to 3 episodes per patient/ year to 0.1 to 0.2 episodes per patient/ year) and may also 
prevent episodes of pyelonephritis (Hooton 2001). Notably, one agent is not recommended 
over another because studies to date have lacked sufficient statistical power. In general, 
antimicrobial prophylaxis is initiated on a trial basis for a 6 month period. If good outcomes 
are reported the agent may be continued for 2 to 5 years without the emergence of a 
resistant organism (Stamm et al. 1991). The rate of chronic adverse effects associated with 
antimicrobial agents ranges from 7% to 40% for trimethoprim containing regimens, from 0% 
to 40% for nitrofurantoin, from 7 to 21% for norfloxacin and up to 13% for ciprofloxacin 
(Chew and Fihn 1999). Gastrointestinal disturbances, rash and yeast vaginitis are the most 
common adverse effects encountered (Fig. 5). 
 
 
Fig. 5. Common adverse effects associated with long-term antimicrobial prophylaxis against 
recurrent episodes of cystitis. 
Post-coital prophylaxis is an attractive option for female patients that describe a direct 
association between sexual intercourse and subsequent cystitis. A reduction in the frequency 
of recurrences has been demonstrated when nitrofurantoin, TMP-SMX or fluroquinolones 
have been administered post-coitus (Stapleton et al. 1990) (Table 8). Intermittent self-
treatment as opposed to continuous treatment has also been recommended in some 
scenarios. Many females can accurately self-diagnose acute cystitis and may be instructed to 
www.intechopen.com
 
Current Management Strategies for Uncomplicated and Complicated Cystitis 
 
29 
commence a 3-day course of an antimicrobial agent at the onset of symptoms (Gupta et al. 
2001a). However, females are advised to seek medical attention if symptoms persist 48-72 
hours after completing the appropriate antimicrobial course. Interestingly, several studies 
have also demonstrated that postcoital voiding does not play a preventative role for 
recurrent cystitis. In addition, it appears that poor urinary hygiene does not predispose to 
recurrent cystitis (Scholes et al. 2000, Strom et al. 1987). 
 
Regimen 
Infections per 
patient per year
Reference 
Nitrofurantoin, 50 or 100 mg daily 0.09 (Bailey et al. 1971) 
Nitrofurantoin, 50mg daily 0.19  
Placebo 2.1  
Sulfamethoxazole, 500mg daily 2.5 (Harding et al. 1982) 
TMP-SMX, 40 and 200mg daily 0.1  
Methenamine mandelate, 2g daily + acorbic 
acid 2g 
1.6  
Nitrofurantoin, 50mg daily 0.32 (Kasanen et al. 1978) 
Methenamine hippurate, 1g daily 0.39  
Trimethoprim, 100mg daily 0.13  
TMP-SMX, 80 and 400 mg daily 0.19  
Cephalexin, 125 mg daily 0.10 (Gower 1975) 
TMP-SMX, 40 and 200 mg daily 0.00 (Stamey et al. 1977) 
Nitrofurantoin marcocrystals, 100mg daily 0.74  
TMP-SMX, 40 and 200 mg 3-times weekly 0.1 (Harding et al. 1979) 
TMP-SMX, 40 and 200 mg daily 0.15 (Stamm et al. 1980) 
Trimethoprim, 100 mg daily 0.00  
Nitrofurantoin marcocrystals, 100mg daily 0.14  
Placebo 2.8  
Nitrofurantoin, 50 mg twice daily 0.19 (Brumfitt et al. 1981) 
Methenamine hippurate, 1g twice daily 0.57  
TMP-SMX, 40 and 200 mg 3-times weekly 0.14 (Harding et al. 1982) 
Trimethoprim, 100 mg daily 1.53 (Brumfitt et al. 1983) 
Methenamine hippurate, 1g daily 1.38  
Povidone-iodine wash, twice daily 1.79  
TMP-SMX, 40 and 200 mg daily 0.2 (Wong et al. 1985) 
Self-administered cotrimoxazole, 4 x 80 and 
400mg 
2.2  
Cephalexin, 250 mg daily 0.18 (Martinez et al. 1985) 
Trimethoprim, 100 mg daily 1.0 (Brumfitt et al. 1985) 
Nitrofurantoin macrocrystals, 100 mg daily 0.16  
Nitrofurantoin, 200 mg daily 0.00 (Nicolle et al. 1989) 
Norfloxacin, 200 mg daily 0.00  
Norfloxacin, 200 mg daily 0.04 (Raz and Boger 1991) 
Table 8. Low-dose prophylactic regimes for recurrent cystitis in females. 
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5. Conclusions  
It is important for urologists to be familiar with appropriate management strategies for 
cystitis because of its highly prevalent nature in the community. Currently, recommended 
treatment regimens for uncomplicated cystitis include 3-day therapy with fluroquinolones 
or nitrofurantoin as resistance rates appear to be increasing when TMP-SMX is 
administered. Worryingly, recent studies have demonstrated an increasing number of 
isolates of fluoroquinolone-resistant pathogens and this merits concern for the future. 
Female patients that complain of frequent recurrences should be advised to avoid exposure 
to vaginal spermicides and prophylaxis or methods of self-administration may be 
considered. Imaging studies should be reserved for patients presenting with complicated 
episodes of cystitis. The increasing incidence of antimicrobial resistance in conjunction with 
the highly prevalent nature of cystitis suggests that prudent and appropriate use of 
antimicrobial agents is becoming increasingly important. 
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